Related Experiment Video
Updated: Jun 11, 2026

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
HDM2 impairs Noxa transcription and affects apoptotic cell death in a p53/p73-dependent manner in neuroblastoma
Yun Shi1, Hisanori Takenobu, Kenji Kurata
1Division of Biochemistry and Molecular Carcinogenesis, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuoh-ku, Chiba 260-8717, Japan.
Abstract:
HDM2, a human homologue of MDM2, is a major negative regulator of p53 function, and increased expression of HDM2 by its promoter polymorphism SNP309 resulted in p53 inactivation and an increased risk of several tumours, including neuroblastoma (NB). Herein, we show that increased expression of HDM2 is related to a worse prognosis in MYCN-amplified NB patients. HDM2 plays an important role in the expression of Noxa, a pro-apoptotic molecule of the Bcl-2 family, which induces NB cell apoptotic death after doxorubcin (Doxo) treatment. Knockdown of HDM2 by siRNA resulted in the upregulation of Noxa at mRNA/protein levels and improved the sensitivity of Doxo-resistant NB cells, although these were not observed in p53-mutant NB cells. Noxa-knockdown abolished the recovered Doxo-induced cell death by HDM2 reduction. Intriguingly, resistance to Doxo was up-regulated by over-expression of HDM2 in Doxo-sensitive NB cells. By HDM2 expression, p53 was inactivated but its degradation was not accelerated, suggesting that p53 was degraded in a proteasome-independent manner in NB cells; downstream effectors of p53, p21(Cip1/Waf1) and Noxa were suppressed by HDM2. Noxa transcription was considerably regulated by both p53 and p73 in NB cells. Furthermore, in vivo binding of p53 and p73 to Noxa promoter was suppressed and Noxa promoter activation was inhibited by HDM2. Taken together, our results may indicate that the HDM2-related resistance to chemotherapeutic drugs of NB is regulated by p53/p73-dependent Noxa expression in NB.
Insights
Increased HDM2 expression worsens prognosis in neuroblastoma (NB) by suppressing Noxa, a key apoptosis regulator. Reducing HDM2 restores chemotherapy sensitivity in NB cells, highlighting a potential therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- HDM2 negatively regulates p53 tumor suppressor activity.
- Increased HDM2 expression, often due to SNP309 polymorphism, is linked to various cancers, including neuroblastoma (NB).
- MYCN-amplified NB is an aggressive subtype with poor prognosis.
Purpose of the Study:
- To investigate the role of HDM2 in MYCN-amplified NB prognosis and its impact on chemotherapy response.
- To elucidate the mechanism by which HDM2 influences NB cell sensitivity to doxorubicin (Doxo).
Main Methods:
- Small interfering RNA (siRNA) to knockdown HDM2 expression.
- Quantitative real-time PCR and Western blotting to assess mRNA and protein levels of Noxa.
- Cell viability assays to determine sensitivity to doxorubicin.
- Chromatin immunoprecipitation (ChIP) assays to evaluate p53/p73 binding to the Noxa promoter.
Main Results:
- Elevated HDM2 expression correlates with a worse prognosis in MYCN-amplified NB patients.
- HDM2 knockdown upregulates Noxa (mRNA/protein) and resensitizes Doxo-resistant NB cells, an effect dependent on p53 status.
- HDM2 overexpression confers Doxo resistance in sensitive NB cells.
- HDM2 inhibits p53/p73 binding to the Noxa promoter, suppressing its transcription and downstream apoptosis.
Conclusions:
- HDM2 plays a critical role in mediating doxorubicin resistance in neuroblastoma.
- The HDM2-Noxa axis, regulated by p53/p73, represents a potential therapeutic vulnerability in NB.
- Targeting HDM2 may restore chemosensitivity in drug-resistant neuroblastoma.
Related Concept Videos
Abnormal Proliferation
The Intrinsic Apoptotic Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
